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Abstract
Background: A recent drug interaction study reported that when azithromycin was administered with the combination of
ivermectin and albendazole, there were modest increases in ivermectin pharmacokinetic parameters. Data from this study
were reanalyzed to further explore this observation. A compartmental model was developed and 1,000 interaction studies
were simulated to explore extreme high ivermectin values that might occur.
Methods and Findings: A two-compartment pharmacokinetic model with first-order elimination and absorption was
developed. The chosen final model had 7 fixed-effect parameters and 8 random-effect parameters. Because some of the
modeling parameters and their variances were not distributed normally, a second mixture model was developed to further
explore these data. The mixture model had two additional fixed parameters and identified two populations, A (55% of
subjects), where there was no change in bioavailability, and B (45% of subjects), where ivermectin bioavailability was
increased 37%. Simulations of the data using both models were similar, and showed that the highest ivermectin
concentrations fell in the range of 115–201 ng/mL.
Conclusions: This is the first pharmacokinetic model of ivermectin. It demonstrates the utility of two modeling approaches
to explore drug interactions, especially where there may be population heterogeneity. The mechanism for the interaction
was identified (an increase in bioavailability in one subpopulation). Simulations show that the maximum ivermectin
exposures that might be observed during co-administration with azithromycin are below those previously shown to be safe
and well tolerated. These analyses support further study of co-administration of azithromycin with the widely used agents
ivermectin and albendazole, under field conditions in disease control programs.
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Introduction
The operational efficiency of disease elimination programs in
developing countries could be improved by integrating delivery of
several interventions at local (village and district) levels [1–3]. In
areas endemic for co-infection with filarial nematodes and
Chlamydia trachomatis, one such integrated disease elimination
strategy would be based on mass administration of a three-drug
combination: ivermectin for onchocerciasis, albendazole for
lymphatic filariasis and azithromycin for trachoma. Regular
administration of this combination would also be predicted to
reduce other infectious agents including soil transmitted nema-
todes and bacterial sexually transmitted diseases [4].
A recent pharmacokinetic study evaluated co-administration of
azithromycin, ivermectin and albendazole [5], and showed that
mean ivermectin pharmacokinetic parameters, area under the
concentration-time curve (AUC) and maximum concentration
(Cmax), were increased by 31% and 27%, respectively relative to a
baseline period. The variability in this interaction was large, with
two individuals having 3-fold increases in ivermectin AUC.
Increased ivermectin exposures could potentially have safety
implications, as high dose ivermectin animal studies and
observations of human overdose have reported signs and
symptoms of central nervous system (CNS) toxicity including
emesis, mydriasis and ataxia [6]. However a recent safety study
demonstrated no significant toxicity in the CNS or other body
systems, with ivermectin doses up to 10 times the highest labeled
dose of 200 mg/kg [7,8].
The purpose of this analysis was to model the ivermectin
pharmacokinetic data from the recently reported interaction study
[5], to further characterize the interaction, and explore the sources of
variabilities between subjects and across treatments. The model was
also used to simulate the outcomes of 1000 trials, to ensure that peak
ivermectin exposures seen during co-administration did not exceed
those observed in the high dose safety and pharmacokinetic study [7].
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Study Design and Data Assembly
Data from a historical Phase I study with intensive sampling in
healthy subjects was used to develop a population pharmacoki-
netic model for ivermectin [5]. All subjects provided written
informed consent according to local requirements before entering
the study, and the protocol and Informed Consent Form were
approved by the local Institutional Review Board. This was a
three-arm crossover study, where subjects were administered
single-dose regimens of the following treatments in random order:
(i) azithromycin 500 mg; (ii) ivermectin 200 mg/kg of total body
weight rounded to the nearest 3 mg plus albendazole 400 mg;
and, (iii) all 3 drugs administered concurrently. All doses were
administered with 240 mL of water and a standardized breakfast.
Prior to dosing and breakfast, subjects fasted overnight and then
abstained from any further food for 4 hours after study drug
administration. Study arms were separated by washout periods of
3 weeks. Full details of the study are provided in [5].
Blood samples were collected predose and at 0.5, 1, 1.5, 2, 3, 4,
6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours after drug
administration during each of the study phases. Samples were
collected into heparinized Vacutainers. Blood samples were
centrifuged at 3000 rpm for 15 minutes and the plasma samples
were collected in plain plastic tubes without anticoagulant and
then stored at 280uC. Samples were shipped frozen overnight on
dry ice to BAS Analytics (West Lafayette, IN) for sample analyses.
Ivermectin is detected in the body as two metabolites (22,23-
dihydroavermectin-B1a (H2B1a) and 22,23-dihydroavermectin-
B1b (H2B1b), and these were assayed using a validated high
performance liquid chromatography system with liquid chroma-
tography/mass spectrographic detection. The assays were linear
over the ranges of 2.5–1000.0 ng/mL and 2.5–20.0 ng/mL,
respectively. The precision values for both assays were ,10%. In
terms of accuracy, while the bias was not exceeded (615%) for
H2B1b for either the high or low quality control (QC) samples,
they were for H2B1a during long-term stability testing (221.8% at
the low QC and 217.3% for the high QC) (see [5]). Plasma
concentration-time data were analyzed using standard noncom-
partmental analytical software (WinNonlin 4.1; Pharsight Corpo-
ration, Mountain View, CA), and key parameters are shown in
Figure 1. The data analysis presented here is for ivermectin data
from the ivermectin plus albendazole arm (Baseline Phase), and
from the ivermectin, albendazole plus azithromycin arm (Interac-
tion Phase).
Eighteen healthy Caucasian volunteers were enrolled in and
completed this study (9 males and 9 females, mean [6SD] age,
39.4610.5 years, weight 78.2612.4 kg, ivermectin dose
15.562.6 mg).
Pharmacokinetic Modeling
All the data from both arms of the cross-over study were fitted
simultaneously. The data set contained pooled pharmacokinetic,
demographic/covariate, and dosing information. Data were
analyzed using nonlinear mixed-effects modeling with the
NONMEM software system, Version V, Level 1.1 (GloboMax
LLC, Ellicott City, MD) with the PREDPP model library and
NMTRAN subroutines. Computer resources included personal
computers with Intel Pentium 4 processors, Windows XP
Professional operating system, the GNU Fortran Compiler,
GCC-2.95 (Win-32 version also known as G77; GNU Project,
http://www.GNU.org/). Key pharmacokinetic parameters from
the modeling are described in Figure 1.
The first-order conditional estimation method with g-e
interaction (FOCEI) was employed for all model runs. Individual
estimates of pharmacokinetic parameters were obtained using
POSTHOC (an empirical Bayesian estimation method). The
random effect models sufficiently described the error distributions.
For this analysis all interindividual errors were described by
exponential error models on selected parameters (Equation 1).
Pi~^ P P exp gPi 
ð1Þ
where: Pi is the true parameter value for individual i, ^ P P is the
typical population value (geometric mean) of the parameter, g
Pi
are individual-specific interindividual random effects for individual
i and parameter P and were assumed to be independently and
identically distributed following a normal distribution with mean 0
and variance omega (v) squared (g,N(0, v
2)).
The data could not support a full covariance block for the
OMEGA matrix. Modeling began with the assumption of no
covariance between interindividual random effects (diagonal v
matrix). Later, the covariance between clearance (CL) and volume
of distribution in the central compartment (Vc) was estimated. For
pharmacokinetic observations in this analysis, the residual error
model was described by a combined additive and proportional
error model (Equation 2).
Cij~^ C Cij 1zepij

zeaij ð2Þ
where: Cij is the jth measured observation (plasma concentration)
in individual i, ^ C Cij is the jth model predicted value (plasma
concentration) in individual i, epij and eaij are proportional and
additive residual random errors, respectively, for individual i and
measurement j and are assumed to be independently and
identically normally distributed, following a normal distribution
with mean 0 and variance sigma (s) squared (e,N(0, s
2)). For
each treatment arm, separate residual errors were explored. The
pharmacokinetic models were evaluated for goodness of fit and
were then subjected to predictive check model evaluation. For
more detailed technical information on these methods, please see
NONMEM user’s guide [9].
After the structural pharmacokinetic model was established,
known physiologic relationships were incorporated into the
covariate-parameter models. For example, the change in
physiologic parameters as a function of body size was both
theoretically and empirically described by an allometric model
Author Summary
This paper describes the use of a modeling and simulation
approach to explore a reported pharmacokinetic interac-
tion between two drugs (ivermectin and azithromycin),
which along with albendazole, are being developed for
combination use in neglected tropical diseases. This
approach is complementary to more traditional pharma-
cokinetic and safety studies that need to be conducted to
support combined use of different health interventions. A
mathematical model of ivermectin pharmacokinetics was
created and used to simulate multiple trials, and the
probability of certain outcomes (very high peak blood
ivermectin levels when given in combination) was
determined. All simulated peak blood levels were within
ranges known to be safe and well tolerated. Additional
field studies are needed to confirm these findings.
Ivermectin Population PK Model Analysis
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TVP~hTVP:
WTi
WTref
 hallo
ð3Þ
where: the typical individual value of a model parameter (TVP)
was described as a function of individual body weight (WTi),
normalized by a reference weight (WTref), which was 70 kg. hTVP
is an estimated parameter describing the typical pharmacokinetic
parameter value for an individual with weight equal to the
reference weight and hallo is an allometric power parameter
(which can be estimated or fixed to a value of 0.75 for clearances,
and a value of 1 for anatomical volumes).
Population Pharmacokinetic Model Development
Assessment of model adequacy and decisions about increasing
model complexity were driven by the data and guided by
goodness-of-fit criteria, including: (i) visual inspection of diagnostic
scatter plots (observed vs. predicted concentration, residual/
weighted residual vs. predicted concentration or time, and
histograms of individual random effects; (ii) successful convergence
of the minimization routine with at least 2 significant digits in
parameter estimates; (iii) plausibility of parameter estimates; (iv)
precision of parameter estimates; (v) correlation between model
parameter estimation errors ,0.95, and (vi) the Akaike Informa-
tion Criterion (AIC), given the minimum objective function (OBJ)
value and number of estimated parameters [9]. The criteria for
successful runs were restricted to successful convergence using
FOCE with interaction, good diagnostics for the model-fit for all
data of the different treatment periods, and reasonable estimates
for fixed and random effect parameters. Model evaluations
included comparisons of the OBJ between hierarchical models.
A decrease in OBJ corresponding to a chi-square distribution with
a=0.01 and degrees of freedom equal to the difference in the
number of estimated parameters between the two models was used
as the criterion for model comparisons.
Final model parameter estimates were reported with a measure
of estimation uncertainty including the asymptotic standard errors
(obtained from the NONMEM $COVARIANCE step). A limited
covariate modeling approach emphasizing parameter estimation
given the available data, rather than stepwise hypothesis testing,
was implemented for this population pharmacokinetic analysis.
The study population contained equal numbers of males and
females. As such, age, weight and gender were explored as
potential covariates. First, pre-defined covariate-parameter rela-
tionships were identified based on exploratory graphics, mecha-
nistic plausibility of prior knowledge, and then a full model was
constructed, with a fixed allometric relationship of body weight on
clearance and volume parameters. Interindividual variability could
not be incorporated on all fixed-effects parameters to get successful
FOCE runs. For residual variance, a separate residual error was
assigned for each of the treatment arms. A combined additive and
proportional error model was used with 4 parameters to be
estimated for the residual error. Various population models were
evaluated, but only two models that best described the data (as
determined by the log likelihood criterion and visual inspection)
are presented. The first modeling approach was a population
Figure 1. Key pharmacokinetic parameters.
doi:10.1371/journal.pntd.0000236.g001
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parameters and their variances were clearly not normally
distributed, and showed asymmetric distribution, a mixture model
was developed.
Mixture Model
A second modeling approach was a population mixture model
as it met our criteria for model adequacy and provided supporting
evidence of the dichotomy of the observed individual data. Each
subpopulation would have an associated submodel with different
fixed or random effects. This model was adopted to accommodate
the fact that only some of the individuals exhibited a pronounced
increase in ivermectin bioavailability during the interaction arm of
the study. It was preferred over a population model with and
without outlier individuals, as it gave a better fit to the data as
measured by change in OBJ, and met our criteria for a successful
run in terms of a complete successful convergence with reasonable
estimate for precision for both fixed and random effects.
Model Evaluation
Model development was guided by various goodness-of-fit criteria,
including diagnostic scatter plots. Checking of the individual fits was
also employed as part of judging the model performance for each
patient. The final model and parameter estimates were then
investigated with the predictive check method. This method was
similar to the previously described posterior predictive check, but
assumes that parameter uncertainty is negligible, relative to
interindividual and residual variance [11]. The basic premise is that
a model and parameters derived from an observed data set should
produce simulated data that are similar to the original observed data.
The predictive check is a useful adjunct to typical diagnostic plots, in
that the predictive check provides information about the performance
of random-effects parameter estimates, whereas typical diagnostic
Figure 2. Ivermectin AUC ratio (AUC in interaction phase/AUC
in baseline phase) versus azithromycin AUC in interaction
phase. Solid line serves as a reference point of no change of ivermectin
bioavailability; dotted line is Loess fit (local regression fit) to indicate
lack of linear relationship. Circles are the observed individual values.
doi:10.1371/journal.pntd.0000236.g002
Figure 3. Two-compartment pharmacokinetic structural model for ivermectin. The best fit was obtained by models for two subpopulation
(A and B), characterized by different F values, relative to the baseline model that included all subjects. Parameters: central and peripheral
compartment volumes, total body clearance (CL), inter-compartmental clearance (Q), rate of absorption, and relative bioavailability (F). Note that
albendazole was administered in both baseline and interaction phases.
doi:10.1371/journal.pntd.0000236.g003
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estimates. The predictive check model evaluation step was performed
by using the final model and its parameter estimates to simulate data
under the same experimental design of the original data.
One thousand Monte Carlo simulation replicates of the original
data set were generated using the final non-mixture and mixture
population pharmacokinetic models. Distributions of Cmax across
all data simulations were compared with Cmax distribution in the
observed data set. The simulated data from each of the 1000 virtual
trials(18000 subjects for each treatmentperiod)were assembled, and
the similarity between the actual observed data and simulated data
was examined by comparing the 95% predictions intervals of the
simulated data with the original observed data.
Results
Assessment of the relationship between azithromycin and
ivermectin by noncompartmental analysis showed that mean
ivermectin AUC and Cmax was increased by 31% and 27%,
respectively (see [5] for complete results). Visual inspection of the
magnitude of ivermectin accumulation against azithromycin
exposure in the interaction arm showed no obvious relationship
(Figure 2), and a very low Pearson’s r
2 (0.03).
Model
Ivermectin concentration-time data were best described by a
two-compartment pharmacokinetic model with first-order elimi-
nation and absorption (Figure 3). Covariance between CL and Vc
elements of the OMEGA matrix was incorporated in the model.
The use of different residual variance models stratified by the
treatment with and without shared additive components was
explored and incorporated into the structural model. Inclusion of
age or gender as covariates did not contribute additional
information for explaining pharmacokinetic variability based on
OBJ differences in hierarchical models, model convergence, as
well as diagnostic graphics. Therefore, none of these covariates
was included as a covariate in the final population pharmacoki-
netic model. Importantly, the available data for this investigation
contained a relatively small number of subjects and a limited age
range, and so formal hypothesis (significance) testing for covariate
effects was not considered.
The final non-mixture model had 7 fixed-effect parameters and
8 random-effect parameters as shown in Table 1. Population
pharmacokinetic parameters (CL, Vc, Q, Vp; see Figure 1) were
standardized to a 70 kg person using the allometric size model
[10]. In parametric nonlinear mixed effects modeling, the
distribution of gs is assumed to be normal (mean=0, varian-
ce=v
2). With each model developed, we checked the distribution
of gs, and their mean values. The g distribution indicated a clear
violation of the normality assumption. It was necessary to modify
the original model to improve g distribution diagnostics. A mixture
modeling approach was considered as the distribution of some of
the pharmacokinetic parameters and inter-individual variabilities
indicated a lack of homogeneity. The final mixture model had 9
fixed-effect parameters and 8 random-effect parameters as shown
in Table 2. Goodness-of-fit plots for the final model are shown in
Figure 4. The mixture model differed from the non-mixture model
in only two parameters: one defining the difference between the
two subpopulation in terms of bioavailability, the second defining
Table 1. Final Non-Mixture Model Parameter Estimates and
Their Variabilities.
Parameter (unit)
Point
Estimate SEE %RSE %IIV
Fixed Effect Parameters
hCL (L/h) 11.8 3.87 32.79
hVc (L) 195 123 63.07
hKa(1/h) 0.24 0.11 45.83
hQ (L/h) 18.9 8.99 47.56
hVp (L) 882 415 47.05
h trt effect on Ka 1.42 0.295 20.77
h trt effect on F 1.14 0.034 2.98
Inter-individual Variability
vCL 0.023 0.109 473.913 15.165
Cov CL, Vc 20.011 0.055 2500 10.488
vVc 0.063 0.093 147.619 25.099
vF1 0.061 0.061 100 24.698
Residual Variability
s
2
Baseline prop 0.099 0.025 25.25
s
2
Baseline add 0.00
s
2
co-admin prop 0.081 0.033 40.74
s
2
co-admin add 0.00
Point Estimate=Final Parameter Estimates for hs, vs,a n dss; SEE=standard
error of estimates; %RSE=relative standard error (100
*(SEE/Estimate));
IIV(%CV)=interpatient variability (100
*sqrt(Estimate for v
2)); v
2: random effect
parameter that represents inter-patient variance; s
2: random effect parameter
that represents residual variance.
doi:10.1371/journal.pntd.0000236.t001
Table 2. Final Mixture Model Parameter Estimates and Their
Variabilities.
Parameter (unit)
Point
Estimate SEE %RSE %IIV
Fixed Effect Parameters
hCL (L/h) 12.30 5.24 42.60
hVc (L) 190 164 86.32
hKa(1/h) 0.24 0.11 44.54
hQ (L/h) 19.0 8.61 45.32
hVp (L) 841 412 48.99
h trt effect on Ka 1.38 0.16 11.67
h F1 Subpop A 0.99 0.24 23.84
h F1 Subpop B 1.37 0.16 11.90
hmix proportions 0.55 0.47 86.47
Inter-individual Variability
vCL 0.04 0.19 497.31 19.29
Cov CL, Vc 0.01 0.08 1605.11 27.80
vVc 0.08 0.12 158.91 7.13
vF1 0.07 0.09 127.76 26.57
Residual Variability
s
2
Baseline prop 0.09 0.02 25.28
s
2
Baseline add 0.00
s
2
co-admin prop 0.08 0.02 29.40
s
2
co-admin add 0.00
See Table 1 for explanation of abbreviations.
doi:10.1371/journal.pntd.0000236.t002
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Using this approach, inter-individual variability distribution was
modeled as two subpopulations (A and B). The unknown mixture
distribution was estimated at an individual level. The estimate for
each subpopulation included different fixed effects parameters,
different variance parameters, estimation of fraction of individuals
in each subpopulation, and each individual was assigned to the
most likely subpopulation. The proportion of subjects in
subpopulations A and B was estimated as 55% and 45%,
respectively.
Population Pharmacokinetic Analysis
Both the population and individual predictions adequately
described the AUC profiles for each subject (Figure 5), as displayed
by the baseline and interaction phases for subpopulation B. A
similar fit of individual data was observed for Subpopulation A
(data not shown). Figure 6 displays median, 97.5th, and 2.5th
quantiles of the simulated data as lines with the observed data
plotted as individual points. Less than 5% of the observed data
were outside these 95% prediction intervals. No biased pattern or
any tendency for over- or underestimation was noted for the
different treatment periods, or for the two subpopulations. This
finding gives confidence in the model performance in predicting
the expected ivermectin exposures under different circumstances.
Simulations
Simulated maximum concentrations for each individual’s
Cmax values were summarized across 1000 simulation replicates
of the original population pharmacokinetic database and plotted
as box plots (Figure 7). The upper panel shows box plots of the
Figure 4. Goodness-of-fit plots for the final population mixture model. Observed versus predicted and individual predicted plasma
ivermectin levels. The solid line represents the line of identity (top panels). Residual versus predicted plasma ivermectin levels and weighted residual
versus time, (bottom panels).
doi:10.1371/journal.pntd.0000236.g004
Ivermectin Population PK Model Analysis
www.plosntds.org 6 May 2008 | Volume 2 | Issue 5 | e236observed ivermectin Cmax for baseline and interaction periods
for all subjects, and for the two subpopulations. The lower panel
shows box plots for ivermectin Cmax from 1000 simulated trials
for the non-mixture model (all subjects), and the mixture model
(subpopulations A and B). The mixture model pattern predic-
tions for the two subpopulations were very consistent with the
observed data [5]. Extreme values were: non-mixture model:
201.2 ng/mL; mixture model subpopulation A: 115.3 ng/mL;
B: 175.5 ng/mL.
Discussion
There are a number of interesting findings from this analysis of
data from an interaction study of ivermectin and azithromycin.
This is the first published population model of ivermectin
pharmacokinetics. It demonstrates the utility of population
mixture modeling as an approach to explore drug interactions,
especially where there may be population heterogeneity. The
mechanism for the interaction was identified (an increase in
bioavailability in one subpopulation). The model was used to
Figure 5. Observed, population predicted, and individual predicted ivermectin concentrations of individual subjects following
ivermectin alone (No AZ) and after co-administration with azithromycin (AZ) for Subpopulation B, where increased bioavailability
is observed in the interaction period. The solid line represents the fit predicted by the typical pharmacokinetic mixture model parameters. The
dashed line shows the fit of the post hoc estimates of the population model. Circles represent the observed concentrations.
doi:10.1371/journal.pntd.0000236.g005
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that might be observed during co-administration, which permits
comparison with previously published safety and pharmacokinetic
data.
Ivermectin has been approved for use in humans for 2 decades,
yet relatively limited pharmacokinetic data have been published.
Recent studies using modern assay methods have characterized its
pharmacokinetics using noncompartmental methods in the
context of drug combination studies for treatment of onchocer-
ciasis and lymphatic filariasis [12–14], or in high doses for
treatment of head lice [7]. The calculated model parameters are in
close agreement with those determined using noncompartmental
methods [5]. A two compartment model is consistent with the
disposition of ivermectin in man and other species, with a high
volume of distribution into a peripheral compartment [15].
Ivermectin is metabolized extensively in the liver via cytochrome
P450 isozyme (CYP) 3A4 [16]. It is both a substrate for the
transporter P-glycoprotein (Pgp) [17,18], as well as a moderately
potent Pgp inhibitor at concentrations consistent with clinical
exposures in the present study (IC50 0.18–0.4 mM; [19,20]).
The variability of the magnitude of change in ivermectin
pharmacokinetics observed in the interaction phase [5] compli-
cated the interpretation of the presence or absence of a drug
interaction, as the response was very inconsistent among
individuals. One of the objectives of this analysis was to explore
how nonlinear mixed-effects modeling could be used to analyze
such heterogeneous and highly variable experimental data from a
relatively small number of subjects, with intensive pharmacoki-
netic sampling. The initial non-mixture model provided an
adequate description of ivermectin pharmacokinetic data, however
interindividual variability was not homogeneous and could not be
explained by the available covariates. A mixture model was able to
resolve this, and provided an explanation for the observed
differences in bioavailability seen in the clinical study. Mixture
modeling assumes two or more subpopulations exist, rather than a
single homogeneous one [21], and the final model has two
additional fixed parameters, one relating to subpopulation
differences in ivermectin bioavailability, and the other defining
the two subpopulations.
The final mixture model provided a good description of
ivermectin data from both treatment periods. Goodness-of-fit
criteria revealed that the final model was consistent with the
observed data and that no systematic bias remained. The data
points (Figure 4) are scattered closely and randomly around the
line of identity, and the homogenous and random distributions of
weighted residuals indicate the error model was suitable for
describing the variance of the data. The model evaluation results
provided evidence that both the fixed-effects and random-effects
components of the final model were reflective of the observed data
as well. The fact that less than 5% of the data were located outside
Figure 6. Observed data plotted as individual points. The solid center lines represent the median values of the 1000 simulated data sets,
whereas the upper and lower lines represent the 97.5th and 2.5th quantiles of the simulated data, respectively.
doi:10.1371/journal.pntd.0000236.g006
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describes the central tendency and the variability of the data for
the two subpopulations and for the two treatment periods, despite
the large number of parameters and the low number of patients
who participated in the study. The predictive check shows there is
no bias at any phase of the pharmacokinetic profile, which makes
the model useful in predicting ivermectin blood concentrations,
when given alone or co-administered with azithromycin.
Typically, a mixture modeling approach would not be
considered at the outset of a population pharmacokinetic analysis.
Because of the unexplained remaining variability (see above), in
the present analysis, the following decision rules were used in the
evaluation of the mixture model: (i) The Estimation step and
Covariance step terminated successfully; (ii) 95% CI for Mixture
partition did not include 0 nor 1; and (iii) the change in the OBJ
between mixture and non-mixture models was .5.99 (x
2;p ,0.05,
2df). In the present analysis, the difference was 19.8.
The mixture model identified the interaction between azithro-
mycin and ivermectin to be due to changes in bioavailability in
Subpopulation B. Their mean estimate of bioavailability (F) was
1.37 relative to baseline, whereas F was unchanged for
Subpopulation A (0.97). Inspection of noncompartmental data
for Subpopulation B were consistent, showing higher Cmax and
earlier Tmax values (Cmax A: 54.3 ng.h/mL; B: 67.8 ng.h/mL;
Tmax A: 4.1 h; B: 3.4 h). There were no differences in apparent
clearance or volume of distribution. However the mechanism for
the increase in bioavailability is unclear. Azithromycin, like
ivermectin, is a substrate for Pgp, however it has minimal
inhibitory effects on this transporter in vitro [20]. Although
ivermectin is extensively metabolized by CYP3A4 [16], azithro-
mycin has no inhibitory activity against this enzyme [22]. There
are no other plausible metabolic or transporter mechanisms that
could explain an interaction, and no clinical covariates were
identified that characterized either subpopulation. In addition,
mean pharmacokinetic parameters of ivermectin were similar in
both subpopulations in the baseline phase (mean AUC A: 1019; B:
805 ng.h/mL; Cmax A: 52; B: 45 ng/mL; Tmax A: 5.3; B: 4.8h).
The model was used to simulate the range of peak ivermectin
concentrations that might be encountered if azithromycin and
ivermectin were co-administered. These simulated data were then
Figure 7. Upper panel: Observed maximum ivermectin concentration data in baseline and interaction arms from all subjects (open
boxes) and from subpopulations A and B (shaded and hatched boxes). Lower panel: Maximum concentration data from 1000 simulation
replicates using the non-mixture model in all subjects (open boxes) and from the mixture model in subpopulations A and B (shaded and hatched
boxes). The line in the interior of the box denotes the median, the bottom and top edges denote the first and third quartiles, respectively. The lines
from the top and bottom edges extend to 1.5 times the interquartile range. Values exceeding the interquartile range are plotted as individual points.
doi:10.1371/journal.pntd.0000236.g007
Ivermectin Population PK Model Analysis
www.plosntds.org 9 May 2008 | Volume 2 | Issue 5 | e236compared with the Cmax data reported in the high-dose
ivermectin safety study [7]. The median simulated Cmax data
(46.0, 34.1 and 40.3 ng/mL for non-mixture model, mixture
models A and B respectively) were approximately 5–7-fold lower
than the 261 ng/mL value reported by Guzzo et al [7]. Indeed,
the most extreme individual simulated values (201.2, 115.3 and
175.5 ng/mL for non-mixture model, mixture models A and B
respectively) were still lower than the mean value reported in the
high-dose study [7]. These data give a high level of confidence that
peak exposures that are predicted to occur if ivermectin and
azithromycin were co-administered would never exceed mean
values seen under high dose conditions [7], and which in this study
were safe and well tolerated. In the Amsden et al interaction study
[5], ivermectin was dosed with food (a high-fat breakfast). Food
has been shown to increase the bioavailability of ivermectin over
2-fold [7]. Because dosing of patients in Africa is unlikely to be
with high fat meals, extreme peak ivermectin concentrations
would be half of those reported in the simulation.
Interestingly, simulations from both the mixture model and the
non-mixture model had generally similar predictions of ivermectin
exposures (average estimates and variability). Both models
confirmed that the maximum concentration achieved in the
interaction phase would not exceed 201 ng/mL (Figure 7). In spite
of adding two parameters to the non-mixture model; the final
parameter estimates for both models were very similar (Tables 1
and 2). The inflation of variability and projections of extreme
values for both sets of simulations is a consequence of using 1000
replicates, where the chances of sampling from the very extreme
values of random error distributions are more probable. However
predicting extreme high values, even if they are very rare, is very
useful from a safety perspective, and provide a ‘‘worst case’’
scenario of any extreme high exposures that might be encountered
in a clinical setting/trial during co-administration.
There are several important caveats to this analysis. The data
collected from the drug interaction study was not intended for
population analysis, and a larger data set would have been
desirable. The use of a mixture model could be criticized on the
basis that random variations in the data could be ascribed post hoc
to population differences. Indeed, although the mixture model
identified two populations on the basis of different effects on
bioavailability, it is unclear mechanistically what this difference
might be due to. Finally, modeling and simulation can advise but
cannot supplant clinical data. The findings from this study should
be confirmed in further clinical or pharmacokinetic studies.
In conclusion, this analysis demonstrates the utility of a
population model approach to analyze drug interaction data.
The mechanism for the interaction was identified (an increase in
bioavailability in one subpopulation). The model was also used to
simulate multiple clinical trials, to identify the maximum exposures
that might be observed during co-administration, and provides
confidence that the peak ivermectin exposures would never exceed
mean exposures that have previously been shown to be safe and
well tolerated.
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